Disease-specific microbiome transplants—delivered with clinical precision.
LND Therapeutics develops healthy-donor, full-consortia microbiome transplants using proprietary delivery technology for disease-specific clinical applications.
Full-consortia microbiome
Whole-community donor products designed for clinical use.
Disease-specific programs
Distinct products across oncology, non-malignant, and eating disorders.
Clinical portfolio
LND capsule platform
Approved shelf life
12 mo
Storage
−80 °C
rCDI outcome (LND 101)
84 / 84
Product suite
LND 101–103
What is a microbiome transplant?
A microbiome transplant introduces a healthy donor’s full microbial community to help restore ecosystem balance and function. LND’s approach is built around full-consortia products, disease-specific development, and clinical operational readiness.
Disease-specific development
Product strategy is aligned to indication biology (oncology, non-malignant, eating disorders).
Clinical-grade storage
Health Canada approval for a 12-month shelf life with storage at -80°C.
Proprietary delivery technology
A platform designed to deliver donor consortia reliably and consistently.
Evidence-led iteration
Development informed by documented clinical outcomes and ongoing trial programs.
12 mo
Approved shelf life
-80°C
Validated storage
84/84
rCDI cured (LND 101)
3
Clinical-stage products (101–103)
Capsules and analytics
A clinical portfolio across indications, plus analytics to support discovery and monitoring.
LND 101
OncologyCapsule product focused on cancer patients.
Melanoma, lung, pancreatic, renal, breast
Phase 2b / Phase 1 (varies by indication)
LND 102
Non-malignantCapsule product for a range of non-malignant conditions.
ALS, Parkinson’s, Fibromyalgia, MASLD
Phase 1 + Phase 2 planning
LND 103
Low-volumeConcentrated low-volume capsule product for eating disorders.
Anorexia Nervosa
Phase 1
Analysis
Multi-omicsEnd-to-end analytics to support trials and cohorts.
Metagenomics, functional/EC, metabolites, 16S rRNA
Clinician-ready summaries & reproducible reporting
A compliant, repeatable clinical pathway
From donor sourcing to storage and program execution, we support partners with an operational model designed for clinical delivery.
Screen & Qualify
Healthy donor screening and qualification aligned to clinical-grade standards.
Manufacture
Standardized preparation using proprietary technology for consistent delivery.
Store & Supply
Approved 12-month shelf life with storage at -80°C and controlled logistics.
Track & Learn
Program monitoring and analytics to link microbiome changes to outcomes.
Selected outcomes and milestones
A rotating view of clinical outcomes, approvals, and portfolio updates.
LND 101 in recurrent C. difficile: 84/84 cured
Documented 84/84 patients with recurrent C. difficile cured (97.5% one-sided CI of failure rate 0.0–4.3%). (Parvathy S., 2023)
Request the evidence packet →Health Canada-approved 12-month shelf life
Product storage validated at -80°C with a 12-month shelf life approval to support reliable clinical supply.
Explore services →Three clinical-stage products, indication-specific development
LND 101 targets oncology settings, LND 102 covers multiple non-malignant conditions, and LND 103 is a concentrated low-volume product for eating disorders.
See programs →